Comparability and biosimilarity: considerations for the healthcare provider.
about
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatologyBiosimilars in the United States: Considerations for Oncology Advanced PractitionersActive and passive surveillance of enoxaparin generics: a case study relevant to biosimilars.Biosimilar medicines - their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in GastroenterologyBiosimilars: Implications for health-system pharmacists.Formulary Selection Criteria for Biosimilars: Considerations for US Health-System PharmacistsBiosimilars 101: considerations for U.S. oncologists in clinical practiceEtanercept biosimilarsEpoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees.Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs.Biosimilars: part 2: potential concerns and challenges for p&t committees.Drift, evolution, and divergence in biologics and biosimilars manufacturing.Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review.Biosimilar insulins are coming: the top 10 things you should know.The biosimilar insulin landscape: current developments.Biosimilars: new promise for reducing healthcare costs.Biosimilar regulation in the EU.Biosimilar monoclonal antibodies: the scientific basis for extrapolation.Biosimilarity Versus Manufacturing Change: Two Distinct Concepts.Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.Biosimilars for psoriasis: preclinical analytical assessment to determine similarity.Medical specialists' attitudes to prescribing biosimilars.Differentiating biosimilarity and comparability in biotherapeutics.Biosimilars: part 1: proposed regulatory criteria for FDA approval.Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products: letter to the editorMS in the analysis of biosimilars.Biosimilars: Key regulatory considerations and similarity assessment tools.The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics.The process defines the product: what really matters in biosimilar design and production?Biosimilar monoclonal antibodies (mAbs) in oncology.Preventing shortages of biologic medicines.Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.
P2860
Q26766028-9F821D57-1532-47A7-9375-3C18570A2C23Q27025705-042FB237-1600-4012-8E0A-2C9D182A75FEQ33419597-1BD1C58F-CA40-4D51-9F8D-A9DF1381F0B8Q33636715-6C0DD3CD-A649-49AE-B45C-1B357A92F568Q34372394-516B1150-D744-4B80-B825-D325D00FAA4CQ34612781-361D0685-7681-4C11-A126-92F4C2F3CFD5Q35000438-501D0720-9773-4F67-9ECC-0521CDE3F86EQ35020358-673D3859-2849-4614-8832-73767C8C37C6Q35162053-6EFD49D7-E97A-4B7F-9300-8DB5707CE61CQ36164727-DD7CFD0B-0907-4FF8-852B-E50312F4398AQ36215497-602ABBC0-25AF-4344-B72E-08A9783FA542Q37081551-C34A52D1-C214-4A8E-B43C-2BE8432D3155Q38190917-F8B0A7C8-7DBD-4A23-9D5E-D21549CDB3BDQ38201788-DE6C3807-E805-41B5-BFDC-1711C5CDFD0FQ38219486-A36BB1EF-EC1A-41B6-BAB7-A8C2879F38F5Q38270207-EB9E2BD1-0CC7-49FD-A667-3F2C39AAE9F1Q38543585-1A4E1444-909D-4834-AC3B-7C5258C69EB6Q38570723-7EDE1465-8DEC-4DF7-8434-5BD377B193EDQ38586044-8C8B87FC-F51D-4907-AE7D-1C4447C4773CQ38588544-1911CDFC-26B5-4C8D-95C8-9AF6CDE1811EQ38591241-6488B7FF-B833-4BDA-8579-562F382570F1Q38621681-ACE58496-9B10-4D4E-ACA4-8C091490A218Q38944652-89A0BCCD-8F17-4099-9525-03709A62CC6BQ38979267-0516AD06-5473-48EE-A56C-1EBB2AE6FC07Q42545996-03E3537F-2445-4336-8BE9-D296EAB0EA1CQ42846270-CF3EB261-9A86-48FA-A633-67FE9DCDF3E8Q44031303-76CDB712-EC04-49A3-83F4-1D3AA2D6831FQ46729332-15F103D2-DB59-4BAD-A321-6218192B902AQ47796704-D03C5FAC-F9C1-4E02-8D01-D176BF79C71CQ49881176-3B6AFEC5-BD50-41B5-BC6C-3FB796F890C8Q50115805-C7496020-76AF-4F23-9F2C-F7AF909B0DF9Q50207250-C61B5B59-7056-415B-922D-02B398FB51D3Q52646548-7649F7D4-5C69-4AE2-AEFA-C8D3D30B9C05Q54135887-A4E5DEFB-AC35-4840-A0A6-4554D9A97403
P2860
Comparability and biosimilarity: considerations for the healthcare provider.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Comparability and biosimilarity: considerations for the healthcare provider.
@en
type
label
Comparability and biosimilarity: considerations for the healthcare provider.
@en
prefLabel
Comparability and biosimilarity: considerations for the healthcare provider.
@en
P2093
P1476
Comparability and biosimilarity: considerations for the healthcare provider.
@en
P2093
Gustavo Grampp
Jason B Litten
Jaymi F Lee
P304
P356
10.1185/03007995.2012.686902
P407
P577
2012-06-06T00:00:00Z